



IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John F. Engelhardt et al.

Title: COMPOUNDS AND METHODS FOR PHARMICO-GENE THERAPY OF EPITHELIAL SODIUM CHANNEL ASSOCIATED DISORDERS

Docket No.: 875.085US1
Filed: March 31, 2004
Examiner: Unknown

Serial No.: 10/815,557
Due Date: N/A
Group Art Unit: 1653


MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

We are transmitting herewith the following attached items (as indicated with an "X"):


- Return postcard.
- Supplemental Information Disclosure Statement (2 pgs.), Form 1449 (3 pgs.), and copies of 22 cited documents.


If not provided for in a separate paper filed herewith, Please consider this a **PETITION FOR EXTENSION OF TIME** for sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
Customer Number 21186

By: 
Atty: Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 24th day of April, 2006.


Name


Signature

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
(GENERAL)



S/N 10/815,557

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: John F. Engelhardt et al. Examiner: Unknown
Serial No.: 10/815,557 Group Art Unit: 1653
Filed: March 31, 2004 Docket: 875.085US1
Title: COMPOUNDS AND METHODS FOR PHARMICO-GENE THERAPY OF
EPITHELIAL SODIUM CHANNEL ASSOCIATED DISORDERS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :10/815,557

Filing Date: March 31, 2004

Title: COMPOUNDS AND METHODS FOR PHARMICO-GENE THERAPY OF EPITHELIAL SODIUM CHANNEL ASSOCIATED DISORDERS

Page 2

Dkt: 875.085US1

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any U.S. Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,


JOHN F. ENGELHARDT ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date April 24, 2006

By


Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 24th day of April, 2006.

JAMES KAUSISIK
Name



Signature

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	10/815,557
Filing Date	March 31, 2004
First Named Inventor	Engelhardt, John
Group Art Unit	1653
Examiner Name	Unknown

Attorney Docket No: 875.085US1

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-2001/0034349A1	10/25/2001	Boucher, Jr., R. C.	02/20/2001
	US-2001/0041682A1	11/15/2001	Stutts, III, M. J., et al.	05/07/2001
	US-2002/0099023A1	07/25/2002	Boucher, Jr., R. C.	03/01/2002
	US-2002/0115619A1	08/22/2002	Rubenstein, R. C., et al.	10/04/2001
	US-2002/0128203A1	09/12/2002	Schild, L.	09/19/2001
	US-2002/0132770A1	09/19/2002	Caplan, M. T., et al.	10/12/2001
	US-2002/0156057A1	10/24/2002	Bubien, J. K.	04/19/2002
	US-2002/0158255A1	10/31/2002	Boucher, Jr., R. C.	04/12/2002
	US-2002/0165239A1	11/07/2002	Boucher, Jr., R. C.	04/12/2002
	US-2003/0087818A1	05/08/2003	Jiang, Y., et al.	02/01/2002
	US-4,501,729	02/26/1985	Boucher, R. C., et al.	12/13/1982
	US-5,292,498	03/08/1994	Boucher, Jr., R. C.	06/19/1991
	US-5,512,269	04/30/1996	Molina y Vedia, L. M., et al.	06/09/1993
	US-5,628,984	05/13/1997	Boucher, Jr., R. C.	07/31/1995
	US-5,635,160	06/03/1997	Stutts, III, M. J., et al.	06/07/1995
	US-5,651,957	07/29/1997	Molina y Vedia, L. M., et al.	05/02/1995
	US-5,656,256	08/12/1997	Boucher, R. C., et al.	12/14/1994
	US-5,683,675	11/04/1997	Molina y Vedia, L. M., et al.	05/02/1995
	US-5,716,931	02/10/1998	Molina y Vedia, L. M., et al.	05/02/1995
	US-5,725,842	03/10/1998	Boucher, Jr., R. C., et al.	01/05/1996
	US-5,849,706	12/15/1998	Molina y Vedia, L. M., et al.	01/28/1998
	US-5,855,918	01/05/1999	Mrsny, R. J., et al.	09/12/1996
	US-5,876,700	03/02/1999	Boucher, Jr., R. C., et al.	01/31/1997
	US-5,902,567	05/11/1999	Boucher, Jr., R. C.	12/30/1996
	US-5,935,555	08/10/1999	Stutts, III, M. J., et al.	05/08/1977
	US-6,022,527	02/08/2000	Boucher, Jr., R. C., et al.	07/13/1999
	US-6,033,688	03/07/2000	Mrsny, R. J., et al.	09/02/1997
	US-6,133,247	10/17/2000	Boucher, Jr., R. C.	07/24/1996
	US-6,143,279	11/07/2000	Boucher, Jr., R. C., et al.	08/28/1998
	US-6,214,536	04/10/2001	Boucher, Jr., R. C.	11/04/1999
	US-6,235,266	05/22/2001	Stutts, III, M. J., et al.	04/30/1999
	US-6,264,975	07/24/2001	Boucher, Jr., Richard C.	10/20/1999
	US-6,323,187	11/27/2001	Yerxa, B. R., et al.	05/21/1999
	US-6,416,759	07/09/2002	Firestone, G. L., et al.	09/30/1999
	US-6,420,347	07/16/2002	Jacobus, K. M., et al.	03/27/1997
	US-6,451,288	09/17/2002	Boucher, Jr., R. C., et al.	08/24/2000
	US-6,475,509	11/05/2002	Boucher, Jr., R. C.	07/19/2000
	US-6,607,741	08/19/2003	Boucher, Jr., R. C.	04/12/2002
	US-6,613,345	09/02/2003	Boucher, Jr., R. C.	04/12/2002

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/815,557
	Filing Date	March 31, 2004
	First Named Inventor	Engelhardt, John
	Group Art Unit	1653
	Examiner Name	Unknown
Sheet 2 of 3	Attorney Docket No: 875.085US1	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²
	WO-02/24172A1	03/28/2002	Vanderbist, F., et al.	
	WO-02/24177A2	03/28/2002	Schild, L., et al.	
	WO-03/057847A2	07/17/2003	Shuster, S. J., et al.	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AUERBACH, S. D., et al., "Human Amiloride-Sensitive Epithelial Na ⁺ Channel γ Subunit Promoter: Functional Analysis and Identification of a Polypurine-Polypyrimidine Tract With the Potential for Triplex DNA Formation", <u>The Biochemical Journal</u> , 347, (2000), 105-114	
		BAINES, D. L., et al., "Effect of LPS-Induced NF-kB Activity on the Transcriptional Response of a 5' Flanking Region of the α ENaC Gene", <u>Experimental Biology 2003 - Translating the Genome</u> , (Abstract No. 5860) (http://www.biosis-select.org/faseb/data/FASEB005860.html), (2003), 1 pg.	
		BEUTLER, K. T., et al., "Long-Term Regulation of ENaC Expression in Kidney by Angiotensin II", <u>Hypertension</u> , 41, (2003), 1143-1150	
		BOOTH, R. E., et al., "Targeted Degradation of ENaC in Response to PKC Activation of the ERK1/2 Cascade", <u>American Journal of Physiology - Renal Physiology</u> , 284, (2003), F938-F947	
		ECELBARGER, C. A., et al., "Regulation of the Abundance of Renal Sodium Transporters and Channels by Vasopressin", <u>Experimental Neurology</u> , 171, (2001), 227-234	
		FALLIN, R. A., et al., "PMA-Induced Inhibition of Amiloride-Sensitive Sodium Absorption is Partially Mediated by ERK1/2 Activation", <u>The FASEB Journal</u> , 17(5) (Abstracts Part II), (Abstract No. 585-19), (2003), A915-A916	
		GADALLAH, M. F., et al., "Epithelial Sodium Channel-Dependent Hypertension: An Emerging Syndrome", <u>Journal of the American Society of Nephrology</u> , 10 (Abstracts Issue), (Abstract No. A1842), (1999), page 365A	
		GADALLAH, M. F., et al., "Preservation of Renal Function in Patients With Hypertension and Chronic Renal Impairment; Revisited", <u>Journal of the American Society of Nephrology</u> , 10 (Abstracts Issue), (Abstract No. A1841), (1999), page 365A	
		GORMLEY, K., et al., "Regulation of the Epithelial Sodium Channel by Accessory Proteins", <u>The Biochemical Journal</u> , 371, (2003), 1-14	
		HUMMLER, E., et al., "Genetic Disorders of Membrane Transport - V. The Epithelial Sodium Channel and its Implication in Human Diseases", <u>American Journal of Physiology - Gastrointestinal and Liver Physiology</u> , 276, (1999), G567-G571	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1448)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/815,557
	Filing Date	March 31, 2004
	First Named Inventor	Engelhardt, John
	Group Art Unit	1653
	Examiner Name	Unknown
Sheet 3 of 3	Attorney Docket No: 875.085US1	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JORGENSEN, M. J., et al., "Expression of Completely γ -Carboxylated Recombinant Human Prothrombin", <u>The Journal of Biological Chemistry</u> , 262(14), (1987), 6729-6734	
		KAMYNINA, E., et al., "Concerted Action of ENaC, Nedd4-2, and Sgk1 in Transepithelial Na ⁺ Transport", <u>American Journal of Physiology - Renal Physiology</u> , 283, (2002), F377-F387	
		MATALON, S., et al., "Lung Edema Clearance: 20 Years of Progress - Invited Review: Biophysical Properties of Sodium Channels in Lung Alveolar Epithelial Cells", <u>Journal of Applied Physiology</u> , 93, (2002), 1852-1859	
		MIRSHAHI, M., et al., "Paradoxical Effects of Mineralocorticoids on the Ion Gated Sodium Channel in Embryologically Diverse Cells", <u>Biochemical and Biophysical Research Communications</u> , 270, (2000), 811-815	
		NAKAYAMA, M., et al., "Hypomethylation Status of CpG Sites at the Promoter Region and Overexpression of the Human <i>MDR1</i> Gene in Acute Myeloid Leukemias", <u>Blood</u> , 92(11), (1998), 4296-4307	
		ROTIN, D., "Regulation of the Epithelial Sodium Channel (ENaC) by Accessory Proteins", <u>Current Opinion in Nephrology and Hypertension</u> , 9, (2000), 529-534	
		ROTIN, D., et al., "Trafficking and Cell Surface Stability of ENaC", <u>American Journal of Physiology - Renal Physiology</u> , 281, (2001), F391-F399	
		SNYDER, P. M., et al., "Serum and Glucocorticoid-Regulated Kinase Modulates Nedd4-2-Mediated Inhibition of the Epithelial Na ⁺ Channel", <u>The Journal of Biological Chemistry</u> , 277(1), (2002), 5-8	
		THOMAS, C. P., et al., "Genomic Organization of the 5' End of Human β -ENaC and Preliminary Characterization of its Promoter", <u>American Journal of Physiology - Renal Physiology</u> 282, (2002), F898-F909	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached